Test Price
2,800 AED✅ Home Collection Available
CEBPA Gene Somatic Mutation Analysis (NGS) for Acute Myeloid Leukemia (AML) in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Clinical Accuracy Guarantee: 99.9% diagnostic sensitivity for CEBPA mutation detection via ISO 9001:2015 accredited NGS laboratory processing (Cert: INT/EGQ/2509DA/3139).
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection: Available daily from 8 AM to 11 PM.
Post-Test Clinical Guidance: Complimentary telephonic interpretation session with a Consultant Medical Geneticist to discuss NGS findings and next steps.
Insurance Direct Billing Verification: Send your Emirates ID and insurance card via WhatsApp to +971 54 548 8731 for instant pre-approval.
Test Overview & Methodology
The CEBPA somatic mutation analysis using Next-Generation Sequencing (NGS) identifies actionable variants in the CEBPA gene from peripheral blood, extracted DNA, or FTA cards. This test is essential for risk stratification and personalized treatment planning in Acute Myeloid Leukemia (AML), providing high-resolution data on variant allele frequency as low as 5%.
| Feature | Our Test (ISO 9001:2015) | Closest Alternative |
|---|---|---|
| Methodology | NGS – full coding region | Sanger sequencing (single-exon only) |
| Analytical Sensitivity | ≥ 99.9% for variant allele frequency ≥ 5% | ~95% (limited read depth) |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Sample Integrity | Blood, Extracted DNA, or FTA Card (cold-chain) | Whole blood only (fresh) |
Physician Insight & Safety Protocols
"CEBPA mutation status is a critical determinant in AML risk stratification. This NGS test delivers high-resolution genomic data that must be integrated with bone marrow morphology, cytogenetics, and clinical presentation. A negative result does not exclude other myeloid neoplasms; correlation with hematopathology is essential."
— Consultant Medical Genetics Lina Osama Zaki Quteineh, DHA License: 9294403
Advisory: Do Not Modify Prescribed Therapy
Do not discontinue or modify any prescribed medication (including chemotherapy) without consulting your treating oncologist. This test is for diagnostic guidance only and does not replace clinical judgment.
Exclusion Criteria & Emergency Red Flags
- Active severe infection or hemodynamic instability – postpone elective phlebotomy.
- Known allergy to antiseptics or adhesive dressings (inform phlebotomist).
- Pregnancy – only order after genetic counseling and obstetric clearance.
- Minors (<18 years) require documented parental consent as per UAE Federal Law No. 2 of 2019.
- ER Red Flags: Sudden high fever >38.5°C, uncontrolled bleeding, severe bruising, or altered consciousness – proceed to nearest emergency department immediately.
Patient FAQ & Clinical Guidance
1. Why do I need a CEBPA mutation test for AML?
CEBPA mutation analysis classifies AML into prognostic groups (favorable, intermediate, or adverse risk). This information helps your oncologist decide the most appropriate treatment, such as chemotherapy alone or stem cell transplantation. Biallelic CEBPA mutations typically indicate a favorable prognosis and may permit less aggressive therapy.
2. How is the sample collected and is it painful?
A trained phlebotomist will draw a standard blood sample from your vein (or collect a single drop on an FTA card if required) using a small needle. The process is brief and causes minimal discomfort. Pediatric-friendly techniques and topical anesthetics are available upon request.
3. What happens if my CEBPA result is positive?
A positive biallelic CEBPA mutation is generally associated with a favorable prognosis and a higher likelihood of achieving remission with standard chemotherapy. Your hematologist will discuss whether transplant is necessary or whether induction chemotherapy alone is sufficient. Always interpret results alongside bone marrow biopsy findings.
UAE Regulatory & Data Privacy Adherence
Our laboratory operations comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, stored securely, and processed in strict adherence to medical confidentiality standards. ISO 9001:2015 Certified (INT/EGQ/2509DA/3139). DHA Facility License: 1143. DNA Labs UAE is committed to maintaining the highest level of data privacy and clinical integrity.
Clinical & Logistical Metadata
| Test Name | CEBPA Gene Somatic Mutation Analysis (NGS) for AML |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card (cold-chain transport required) |
| Methodology Used | Next-Generation Sequencing (NGS) – full coding region |
| ICD-10-CM Code | C92.00, C92.01, Z15.09 |
| LOINC Code | 69548-6 |
| DHA Facility License & Laboratory Address Invariants | DHA License: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. DNA Labs UAE. |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians